There is provided a pharmaceutical composition which includes, as an active ingredient, a combination drug formulation of potassium citrate and sodium citrate hydrate or a sodium bicarbonate formulation. The prevention or treatment of nocturnal polyuria is achieved by administering the pharmaceutical composition.

The present invention refers to a composition comprising guaifenesin and one or more flavour compound(s) containing an isovanillyl group. In particular, the present invention refers to a composition comprising guaifenesin and one or more flavour compound(s) containing an isovanillyl group, said composition being for medical use, in particular for use in the prevention and treatment of respiratory diseases. Moreover, the present invention relates to the use of guaifenesin and one or more flavour compounds containing an isovanillyl group for the preparation of a pharmaceutical composition. Finally, the present invention relates to the use of one or more flavour compound(s) containing an isovanillyl group for masking or inhibiting the bitter taste of guaifenesin or of guaifenesin comprising compositions.

The present invention relates to a drug for treating leukopenia, its preparation method and use thereof. The drug of the invention is prepared from 200-30 parts by weight of Folium Epimedii, 100-160 parts by weight of Fructus Psoraleae, 60-120 parts by weight of Radix Aconiti Lateralis Preparata (Processed), 200-300 parts by weight of Fructus Lycii, 200-300 parts by weight of Radix Astragali, 200-300 parts by weight of Caulis Spatholobi, 200-300 parts by weight of Radix Rubiae, 100-160 parts by weight of Radix Angelicae Sinensis, 200-300 parts by weight of Rhizoma Phragmitis, 100-160 parts by weight of Radix Ophiopogonis and 100-160 parts by weight of Radix et Rhizoma Glycyrrhizae. The drug of the invention comprises chemical substances with weight ratios as follows: Leucine:guanosine:psoralenoside:isopsoralenoside:calycosin-7-glucoside:liquiritin:icariin A:1,3-dihydroxyl-2-hydroxymethylanthraquinone:epimedin A:epimedin B:epimedin C:icariin:1,3,6-trihydroxy-2-methylanthraquinone:glycyrrhizic acid=(0.13-0.27):(0.04-0.11):(0.11-0.34):(0.09-0.34):(0.05-0.11):(0.16-0.26):(0.09-0.12):(0.17-0.35):(0.11-0.16):(0.17-0.26):(0.49-0.59):1.00:(0.16-0.24):(0.08-0.14).

The disclosure provides an effervescent composition adapted for oral use, the composition including an effervescent material; one or more fillers in a total amount of at least about 30% by weight, the one or more fillers including at least one sugar alcohol; at least one active ingredient; and optionally, a lipid in an amount of at least about 20% by weight. Melting effervescent compositions are also provided, which include the lipid.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

Disclosed herein are immediate release oral dosage forms that comprising esketamine and one or more excipients that produce a visual indication of the presence of the dosage form within a vessel containing a liquid beverage. The visual indication can assist in thwarting an attempt to use the esketamine to render another individual more susceptible to criminal exploitation.

The present disclosure concerns effervescent compositions and methods of making and using the same. In some embodiments, the disclosed effervescent compositions are formed from an input blend comprising an acid and a base by granulating the input blend in a twin-screw processor. The granules formed from the input blend can be formed by an in situ granulating agent, which can be a portion of the acid that melts during granulation. In some embodiments, the effervescent compositions can be made using a twin-screw processor comprising an intake zone for receiving an input blend comprising an acid and a base; a granulation initiation zone for melting only a portion of the acid to serve as an in situ granulating agent; a granulation completion zone for granulating the input blend; and an outlet for discharging the granules.

Composition comprising enzymatically hydrolyzed collagen and cannabidiol, the composition suitable for ingestion by an individual to facilitate improvements in rest, including sleep, and/or in recovery, including but not limited to recovery after physical and/or mental exertion, recovery from pain and combinations thereof, and to facilitate improved delivery to the individual of amino acids comprised in the enzymatically hydrolyzed collagen. Both liquid and particulate compositions comprising full spectrum cannabidiol oil or cannabidiol isolate are provided as well as compositions comprising one or more of a terpene isolate, flavonoid, essential oil, effervescent agent, sweetener or flavoring agent.

The disclosure relates to an effervescent therapeutic composition for delivering multiple compounds to a patient in a single administration. In some embodiments, the effervescent therapeutic composition includes an alkaline effervescing compound, one or more compressible binders, a pharmaceutically acceptable salt of metformin, a pharmaceutically acceptable cobalamin, and an acid compound or an acid salt. In other embodiments, the effervescent therapeutic composition may include a folate or folic acid and metformin. In yet other embodiments, the effervescent therapeutic composition may include a folate or folic acid, cobalamin, and metformin.

Separable microneedle arrays and microneedle patches are provided that may achieve sustained release of drug. The microneedle arrays may include one or more features that facilitate separation of the microneedles, such as a bubble structure. The microneedle arrays may include an effervescent material.